PharmaShots | Incisive News in 3 Shots

Subscribe Now

NSCLC

Blueprint Medicines to Acquire Lengo for ~$250M

Blueprint Medicines to Acquire Lengo for ~$250M

November 30, 2021

PharmaShots Interview: Dr. Trevor Feinstein and BeyondSpring's Dr. Lan Huang Shares Insight on the Data of Plinabulin + Docetaxel for NSCLC with EGFR Wild Type

PharmaShots Interview: Dr. Trevor Feinstein and BeyondSpring's Dr. Lan Huang Shares Insight on the Data of Plinabulin + Docetaxel...

November 8, 2021

Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for 1L Treatment of NSCLC

Roche Entered into a Clinical Trial Supply Agreement with Galecto to Evaluate GB1211 + Tecentriq (atezolizumab) in P-IIa Trial for...

November 3, 2021

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

Biocad Presents Results of BCD-021 (biosimilar, bevacizumab) in P-III Study for the Treatment of NSCLC at ESMO 2021

October 27, 2021

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSCLC

Turning Point and EQRx Collaborate to Evaluate Elzovantinib + Aumolertinib in Patients with EGFR Mutant Met-Amplified Advanced NSC...

October 14, 2021

Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures

Merck KGaA and GSK Terminate their ~$4.2B Collaboration Due to Clinical Failures

October 4, 2021

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us